Fig. 1.

(A) Schematic of the proposed assembly of PSN through specific interactions between MDM2 and peptide 12.1 (not to scale). Inset shows two proposed models for MDM2 bivalency resulting in PSN aggregation from a MDM2 dimerization (e.g., “oligomeric”) conformation (i) and monomeric MDM2 (ii) have two distinct binding sites with the known and an alternative peptide 12.1 binding site (not to scale). (B and C) Extinction spectroscopy (B) and SERS analysis (C) before (dashed) and after (solid line) addition of MDM2 to PSN-12.1.